Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN-587 long-term extension study of pembrolizumab in participants from prior pembrolizumab trials
CTR20210404Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in Nonhematologic neoplasms, hematopoietic malignancies, sponsored by Merck & Co.. Started Dec 2021; status: active.
02
Drugs
03
Conditions
Nonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on CTR20210404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210404.